Get the Stockscreener App
41.50
1.17%
-0.49
Rigel Pharmaceuticals stock is traded at $41.50, with a volume of 894.22K.
It is down -1.17% in the last 24 hours and up +106.88% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
See More
Previous Close:
$41.99
Open:
$42.65
24h Volume:
894.22K
Relative Volume:
2.53
Market Cap:
$744.40M
Revenue:
$116.88M
Net Income/Loss:
$-25.09M
P/E Ratio:
-296.43
EPS:
-0.14
Net Cash Flow:
$-20.74M
1W Performance:
+5.04%
1M Performance:
+106.88%
6M Performance:
+106.57%
1Y Performance:
+243.26%
1-Day Range:
$41.00
$43.72
1-Week Range:
$38.43
$43.72
52-Week Range:
$12.00
$43.72
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
41.50 | 718.75M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
Rigel Pharma’s Comeback: Profits, Pipeline Progress, And A Bargain Price - Finimize
Watch for Bullish Crossover in Rigel Pharmaceuticals Inc.2025 Price Action Summary & Weekly Return Optimization Plans - newsyoung.net
Published on: 2025-08-16 07:20:24 - Newser
Key metrics from Rigel Pharmaceuticals Inc.’s quarterly data2025 Investor Takeaways & Safe Capital Growth Stock Tips - Newser
Is Rigel Pharmaceuticals Inc. a candidate for recovery playJuly 2025 Big Picture & AI Powered Buy/Sell Recommendations - Newser
Published on: 2025-08-16 02:21:32 - Newser
Automated trading signals detected on Rigel Pharmaceuticals Inc.CPI Data & Weekly Breakout Watchlists - Newser
What indicators show strength in Rigel Pharmaceuticals Inc.Trade Performance Summary & Fast Exit and Entry Strategy Plans - Newser
Will a bounce in Rigel Pharmaceuticals Inc. offer an exitJuly 2025 Pullbacks & Expert Verified Movement Alerts - Newser
Has Rigel Pharmaceuticals Inc. found a price floorExit Point & Daily Stock Trend Reports - Newser
Sector ETF performance correlation with Rigel Pharmaceuticals Inc.2025 Dividend Review & Community Consensus Trade Signals - Newser
Forecasting Rigel Pharmaceuticals Inc. price range with options data2025 AllTime Highs & Daily Chart Pattern Signals - Newser
What are Rigel Pharmaceuticals Inc.’s recent SEC filings showingMarket Growth Review & Weekly Stock Breakout Alerts - newsimpact.co.kr
Can volume confirm reversal in Rigel Pharmaceuticals Inc.July 2025 Movers & Safe Capital Investment Plans - Newser
Published on: 2025-08-15 05:51:08 - sundaytimes.kr
Warm Autoimmune Hemolytic Anemia Market to Observe Significant Growth During the Forecast Period | Rigel Pharmaceuticals, Apellis Pharmaceuticals, Inc., Johnson & Johnson, Sanofi, Incyte Corporation - Barchart.com
Rigel Pharmaceuticals Inc. Recovery Linked to Earnings SurprisePortfolio Update Summary & Free Growth Oriented Trading Recommendations - classian.co.kr
Rigel Pharmaceuticals Q2 Earnings Boost Breakout Potential - AInvest
Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout - Seeking Alpha
Rigel Pharmaceuticals (RIGL) up more than 100% since Jul 18 - AInvest
Using Python tools to backtest Rigel Pharmaceuticals Inc. strategiesJuly 2025 Decliners & Breakout Confirmation Alerts - Newser
Rigel Pharmaceuticals' Earnings Mask Underlying Cash Flow Concerns - AInvest
Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are Of Questionable Quality - Yahoo Finance
Technical signs of recovery in Rigel Pharmaceuticals Inc.Oversold Stock Bounce Playbook Generator - Newser
H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL), Sets a $57 PT - Insider Monkey
RIPK1 Inhibitor Pipeline Outlook Report 2025: Key 10+ Companies and Breakthrough Therapies Shaping the Future Landscape - The Globe and Mail
Best Momentum Stock to Buy for August 8th - MSN
Rigel targets up to $280M 2025 revenue as IRA boosts sales and pipeline advances - MSN
Cantor Fitzgerald Analysts Boost Earnings Estimates for RIGL - Defense World
HC Wainwright Issues Positive Estimate for RIGL Earnings - Defense World
Earnings Estimates Moving Higher for Rigel (RIGL): Time to Buy? - Yahoo Finance
Top 5 Stocks with Strong Price Performance to Buy Now - AInvest
5 Best Stocks With Relative Price Strength to Buy Right Now - sg.finance.yahoo.com
Results: Rigel Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
New Strong Buy Stocks for August 8th - TradingView
Rigel Pharmaceuticals reports Q2 EPS $3.91, consensus $1.40 - MSN
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q2 2025 Earnings Call Transcript - Insider Monkey
Rigel Pharmaceuticals Flips To A Profit On Rising Sales - Finimize
Jefferies Reaffirms Their Hold Rating on Rigel (RIGL) - The Globe and Mail
Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Citi Analysts Maintain Buy Rating on Rigel with $67 Price Target - AInvest
Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Up on Better-Than-Expected Earnings - Defense World
Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates - MSN
Rigel Pharmaceuticals’ Earnings Call Highlights Robust Growth - TipRanks
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Raises Target Price to $67 - 富途牛牛
Rigel Pharmaceuticals (NASDAQ:RIGL) Shareholder Returns Have Been Solid, Earning 160% in 1 Year - 富途牛牛
Cantor Fitzgerald Raises Price Target for RIGL to $32.00, Mainta - GuruFocus
Rigel Pharmaceuticals shares surge 16.67% intraday after strong Q2 earnings and revenue guidance. - AInvest
Rigel Pharmaceuticals: Cantor Fitzgerald Maintains Neutral, PT Raised to $32 from $23. - AInvest
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rigel Pharmaceuticals Stock (RIGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schorno Dean L | EVP & Chief Financial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,734 |
38,020 |
57,235 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 04 '25 |
Sale |
20.92 |
2,125 |
44,457 |
53,500 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,796 |
39,379 |
51,704 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 04 '25 |
Sale |
20.92 |
4,952 |
103,601 |
243,854 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 05 '25 |
Sale |
21.93 |
4,400 |
96,474 |
239,454 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 04 '25 |
Sale |
20.92 |
1,448 |
30,294 |
40,169 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 05 '25 |
Sale |
21.93 |
1,339 |
29,359 |
38,830 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):